Geftinat 250mg Tablet (Gefitinib)

Geftinat 250mg – Product Overview

Geftinat 250mg contains gefitinib 250 mg, an oral targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. Gefitinib acts on the epidermal growth factor receptor (EGFR), a protein involved in signalling pathways that can contribute to the growth and survival of cancer cells. Kanta Medicos provides pharmaceutical sourcing and international export support for Geftinat 250mg and other oncology medicines. Availability, documentation, packaging and shipment arrangements are subject to applicable regulations in the destination market. For pharmaceutical distributors, hospitals, pharmacies and other eligible healthcare businesses, contact our export team for product availability and wholesale enquiries.

Geftinat 250mg Composition

Active ingredient: Gefitinib Strength: 250 mg Dosage form: Tablet Therapeutic class: EGFR tyrosine kinase inhibitor Route of administration: Oral Gefitinib 250 mg tablets are used as a targeted treatment in specific patients with non-small cell lung cancer (NSCLC). Treatment selection depends on the patient's diagnosis and tumor molecular characteristics and should be determined by a qualified healthcare professional.

What is Gefitinib?

Gefitinib is a targeted anticancer medicine that inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). By interfering with EGFR signaling, gefitinib can inhibit pathways involved in the growth and proliferation of certain cancer cells. Unlike conventional chemotherapy, targeted therapies such as gefitinib are designed to act on specific molecular pathways associated with cancer cells. The relevance of gefitinib therefore depends on the molecular characteristics of the patient's tumor.

Geftinat 250mg Uses

Gefitinib 250mg is used for certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific EGFR mutations. The U.S. FDA labeling identifies EGFR exon 19 deletions and exon 21 L858R substitution mutations as the mutations relevant to the approved indication for IRESSA (gefitinib). Because cancer treatment depends on tumor type, stage, molecular testing and individual patient factors, Geftinat 250mg should be used only under the supervision of an appropriately qualified healthcare professional.

How Does Gefitinib Work?

Gefitinib belongs to the EGFR tyrosine kinase inhibitor class. EGFR is involved in signaling pathways that regulate cell growth and survival. In some cancers, changes involving EGFR can contribute to uncontrolled cellular growth. Gefitinib inhibits EGFR tyrosine kinase activity and interferes with downstream signaling. This targeted mechanism can reduce signaling that supports the growth of susceptible cancer cells. The effectiveness of treatment depends on the molecular characteristics of the tumor. Appropriate diagnostic and molecular testing should therefore guide treatment decisions.

Geftinat 250mg Dosage Information

The FDA prescribing information for gefitinib states a recommended dose of 250 mg orally once daily, with or without food, for its approved indication. However, patients should not determine their own dose. The prescribing healthcare professional should determine whether gefitinib is appropriate and how it should be used based on the patient's condition, treatment history, laboratory findings and other medicines. Do not change, stop or restart cancer treatment without medical advice.

Important Safety Information

Gefitinib can cause side effects and requires medical supervision. The FDA prescribing information includes important warnings and precautions concerning conditions including:

• Interstitial lung disease
• Liver toxicity
• Gastrointestinal perforation
• Diarrhea
• Ocular disorders including keratitis
• Severe skin reactions

Patients should promptly report new or worsening respiratory symptoms, significant diarrhea, eye symptoms, severe skin reactions or other concerning symptoms to their healthcare professional. This page is intended for general product and pharmaceutical sourcing information and does not replace the prescribing information supplied with the medicine or advice from a qualified healthcare professional.

Geftinat 250mg Storage

Store Geftinat 250mg according to the storage conditions specified on the product packaging and manufacturer's documentation. Keep medicines away from children and avoid using tablets after the expiry date shown on the packaging. For international shipments, storage and transportation should follow the applicable product requirements and destination-market regulations.

Geftinat 250mg Pharmaceutical Export

Kanta Medicos supports international pharmaceutical sourcing and export enquiries for Geftinat 250mg and other oncology products. Our export support can include:

• Product availability enquiries
• Bulk and wholesale sourcing
• Commercial documentation
• Packaging information
• Shipment coordination
• Export documentation support
• Destination-market compliance requirements

Availability and supply arrangements can vary according to destination-country regulations. Buyers should confirm the applicable import, registration and prescription requirements before placing an order.

Geftinat 250mg Wholesale Enquiries

Healthcare distributors, pharmaceutical wholesalers, hospitals and other eligible organizations seeking Geftinat 250mg can contact the Kanta Medicos export team for current product availability and commercial information. For a wholesale enquiry, provide:

• Required quantity
• Destination country
• Preferred packaging
• Delivery requirements
• Required documentation

Our team can then provide information relevant to the proposed pharmaceutical supply requirement.

Related Oncology Products

Kanta Medicos also provides access to other oncology and pharmaceutical products for international sourcing. Explore relevant products and categories:

• [Nindanib 150mg]
• [Cancer Treatment Medicines]

Frequently Asked Questions

 

What is Geftinat 250mg?

Geftinat 250mg contains gefitinib, an EGFR tyrosine kinase inhibitor used for certain patients with non-small cell lung cancer. Gefitinib treatment is associated with specific molecular characteristics of the tumor and should be prescribed by a qualified healthcare professional.

What is the active ingredient in Geftinat 250mg?

The active ingredient is gefitinib, at a strength of 250 mg per tablet.

What is Geftinat 250mg used for?

Gefitinib 250mg is used for certain patients with metastatic non-small cell lung cancer whose tumors have specific EGFR mutations. The FDA-approved indication specifies EGFR exon 19 deletions or exon 21 L858R substitution mutations for the labeled use of gefitinib.

Is Geftinat 250mg a chemotherapy medicine?

Gefitinib is a targeted anticancer therapy classified as an EGFR tyrosine kinase inhibitor. It works by inhibiting EGFR signaling rather than acting as a traditional cytotoxic chemotherapy drug.

How is gefitinib 250mg taken?

The FDA prescribing information specifies 250 mg orally once daily for the approved indication. Individual treatment should always follow the prescribing healthcare professional's instructions.

Can Geftinat 250mg be exported internationally?

Pharmaceutical export is subject to the laws and regulatory requirements of both the exporting and importing countries. Kanta Medicos can provide product and export information for eligible wholesale enquiries, while the buyer/importer remains responsible for applicable destination-market requirements.

How can I enquire about Geftinat 250mg wholesale supply?

Contact the Kanta Medicos export team with the required quantity, destination country and packaging requirements. The team can provide current availability and relevant commercial information.

Request Geftinat 250mg Export Information

For Geftinat 250mg wholesale and international pharmaceutical sourcing enquiries, contact Kanta Medicos with your required quantity, destination country and documentation requirements. Request a wholesale quotation or contact our export team for product availability and further information.